Density of tumor-infiltrating FOXP3+T cells as a response marker for induction chemoradiotherapy and a potential prognostic factor in patients treated with trimodality therapy for locally advanced non-small cell lung cancer

Annals of Thoracic and Cardiovascular Surgery

Volumn 20, Issue 6, 2014, Pages 980-986

  Tao, Hiroyuki ^a   Shien, Kazuhiko ^b   Soh, Junichi ^b   Matsuda, Eisuke ^a   Toyooka, Shinichi ^b   Okabe, Kazunori ^a   Miyoshi, Shinichiro ^b  

^a NATIONAL SANYO HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

FOXP3; Induction chemoradiotherapy; Non small cell lung cancer (NSCLC); Regulatory T cell (Treg); Tumorinfiltrating T cell

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; BIOPSY; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LUNG RESECTION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; T LYMPHOCYTE; TIME; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; T-LYMPHOCYTES; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84918838847     PISSN: 13411098     EISSN: 21861005     Source Type: Journal    
DOI: 10.5761/atcs.oa.13-00237     Document Type: Article

References (31)

1. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007; 25: 313-8
2. Yokomise H, Gotoh M, Okamoto T, et al. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 133: 1179-85
3. Pourel N, Santelmo N, Naafa N, et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 2008; 33: 829-36
4. Decaluwé H, De Leyn P, Vansteenkiste J, et al. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 2009; 36: 433-9
5. Weder W, Collaud S, Eberhardt WE, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010; 139: 1424-30
6. Meacci E, Cesario A, Cusumano G, et al. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radiochemotherapy: the microscopic seed of doubt. Eur J Cardiothorac Surg 2011; 40: 656-63
7. Toyooka S, Kiura K, Takemoto M, et al. Longterm outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for nonsmall- cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg 2012; 14: 565-9
8. Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 2011; 105: 93-103
9. deLeeuw RJ, Kost SE, Kakal JA, et al. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012; 18: 3022-9
10. Shimizu K, Nakata M, Hirami Y, et al. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol 2010; 5: 585-90
11. Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008; 14: 2413-20
12. Aruga T, Suzuki E, Saji S, et al. A low number of tumor- infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable antitumor response in patients with breast cancer. Oncol Rep 2009; 22: 273-8
13. Ladoire S, Mignot G, Dabakuyo S, et al. In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol 2011; 224: 389-400
14. Pölcher M, Braun M, Friedrichs N, et al. Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy- treated ovarian carcinoma. Cancer Immunol Immunother 2010; 59: 909-19.
15. Battaglia A, Buzzonetti A, Monego G, et al. Neuropilin-1 expression identifies a subset of regulatory T cells in human lymph nodes that is modulated by preoperative chemoradiation therapy in cervical cancer. Immunology 2008; 123: 129-38
16. Katayama H, Ueoka H, Kiura K, et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-smallcell lung cancer. Br J Cancer 2004; 90: 979-84
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47
18. de Boer RH, Smith IE, Pastorino U, et al. Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. Br J Cancer 1999; 79: 1514-8
19. Kim AW, Liptay MJ, Bonomi P, et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg 2011; 92: 233-41; discussion 241-3
20. Lococo F, Cesario A, Margaritora S, et al. Induction therapy followed by surgery for T3-T4/N0 non-small cell lung cancer: long-term results. Ann Thorac Surg 2012; 93: 1633-40
21. Kunitoh H, Suzuki K. How to evaluate the risk/benefit of trimodality therapy in locally advanced non-smallcell lung cancer. Br J Cancer 2007; 96: 1498-503
22. Hiraoka K, Miyamoto M, Cho Y, et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006; 94: 275-80
23. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113: 1387-95
24. Ruffini E, Asioli S, Filosso PL, et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009; 87: 365-71; discussion 371-2
25. Wakabayashi O, Yamazaki K, Oizumi S, et al. CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003; 94: 1003-9
26. Mori M, Ohtani H, Naito Y, et al. Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med 2000; 191: 113-8
27. McCoy MJ, Lake RA, van der Most RG, et al. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer. 2012; 107: 1107-15
28. Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-70
29. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15: 5379-88
30. Speiser DE, Migliaccio M, Pittet MJ, et al. Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J Immunol 2001; 31: 459-66
31. Tsuchikawa T, Hirano S, Tanaka E, et al. Novel aspects of preoperative chemoradiation therapy improving anti-tumor immunity in pancreatic cancer. Cancer Sci 2013; 104: 531-5